GBA's "2021 Stock Phantasma"

7/7---> One Stop Systems initiated with a Buy at Lake Street 07/07 OSS Lake Street analyst Eric Martinuzzi initiated coverage of One Stop Systems with a Buy rating and $8 price target. Since CEO David Raun replaced founder Steve Cooper in 2020, the company is pursuing a smaller portion of the high performance computing edge market, called AI Transportables, where it could establish itself as the market leader and achieve better margins, said Martinuzzi. He believes One Stop's new management and more-narrowly focused strategy have it positioned to outperform, the analyst tells investors.

I found this name browsing Seeking Alpha-- I like it's niche.

One Stop Systems(NASDAQ:OSS)is a small, profitable company situated in a high-growth part of the economy. The enterprise designs and builds high-speed computer systems for onboard data environments and rugged uses far from a stable, fixed spot on your office desk or kitchen table. While the big tech leaders are battling each other for cloud and data center supremacy, OSS is focused on military computing in the field, autonomous vehicle data collection, AI decision making, and handheld technologies for harsh outdoor settings.

17314402_16265588254500_rId6.png



17314402_16265588254500_rId10.png


17314402_16265588254500_rId24.png


17314402_16265588254500_rId25.png


Dead on!
 
you know, this research i did into nokia NOK back in january ended up holding up pretty well, though it was a bit of a stab in the dark at the time and i didn't end up keeping the stock. anything under $4 turned out to be a good deal, as stock has risen steadily and they seem to be getting a foothold into 5G


See recent Nok post!
 
WHAT'S UP WITH CHEWIE-? $79 July 8th.....-- Off To $84......

$77!<- NOW!!!! WTF... Now I have made the same mistake with a few stocks. You have seen them go up and then reverse and go down... This is some combination of my being able to spot break outs before they happen and this vicious correction.

CHWY. Why pick on them?

Chewy initiated with an Outperform at Exane BNP Paribas 05:13 CHWY Exane BNP Paribas initiated coverage of Chewy with an Outperform rating and $101 price target.

Update -$83
 
Wonder what these things do to people with pace-makers?
They had to have thought of this.

If they figure out a way to embed them in highways... you wouldn't have to stop and re-charge your EV on a roadtrip. Now then you'd have something.

Anyway... it's a story stock Stoney.... it might pop, but it'll drop. In the last 12 months they had REVENUE of less than a penny/share lol.

A price/sales of 370!

Operating margin -7,731.66%

Pretax margin TTM -7,728.46%

Net Profit margin TTM -7,728.46%

62 Million shares outstanding... and last years revenue was $410,000

Did they get a new contract Stoney?:rolleyes::banghead:

Anyone who buys this stock at $2.50 is an idiot.


LAST ONE---

Van made a nice call here as stk did miss earnings!
It was $2.44 and it went to $2.22. But look at the flurry of
buying there... 1 mil shares followed by 600,000<---
and bam all the way back to $2.60!!!!

The signs are there that there is something to this idea, this name but what?

Energous Corporation (WATT)
$2.5200+0.0900 (+3.70%)
At close: July 30

Thus ends our past 2 week review!!! :cool:

PS:
Evoqua Water Technologies Corp. (AQUA)
$33.01


 
Thurs-Nokia raises FY21 revenue view to EUR 21.7B-EUR 22.7B from EUR 20.6B-EUR 21.8B 05:48 NOK Sees FY21 free cash flow clearly positive. Sees FY21 comparable operating margin 10%-12%.
 
<<3 I FORGOT>>

MTTR--

HOLX--

ECOR--


  • Ladenburg Thalmann has initiated coverage of ElectroCore Inc (NASDAQ: ECOR) with a Buy rating and $3 price target, implying an upside of around 190%.

  • The Company's gammaCore Sapphire device is currently commercially available both in the U.S. and outside the U.S., and analyst Jeffrey Cohen believes that electroCore should be valued in comparison with other innovative healthcare and bioelectric companies, he tells investors.

  • In the U.S., Sapphire has clearance for the treatment and prevention of cluster headaches and migraines. Cohen noted that the gammaCore Sapphire could also be utilized for asthma exacerbations in known or suspected COVID-19 patients under FDA emergency use authorization.

  • The United States Patent and Trademark Office (USPTO) has issued a patent to electroCore, relating to using a mobile phone to stimulate the trigeminal nerve to treat disorders.

  • Price Action: ECOR shares are up 12.9% at $1.05 on robust volume during the premarket session on the last check Tuesday.
 
Sexy investors may want to take a peek at DOWN 20% ATOS!

  • Atossa Therapeutics (ATOS -13.2%) has lost more than a tenth in value in morning hours after the company announced a special meeting of stockholders seeking approval for an amendment to the certificate of incorporation.
  • At the meeting scheduled on September 7, Atossa expects to put to vote a proposal to increase the number of the authorized common stock by 100M.
maybe i should give up trying to find the bottom of ELMS and switch to ATOS instead. will look into it--probably a lot more upside.
 
Back
Top